Differential expression of serum proteins in multiple myeloma

Ma,Tian‑Ze; Piao,Zhe; Jin,Sheng‑Yu; Kwak,Yong‑Geun

doi:10.3892/etm.2018.7010

Differential expression of serum proteins in multiple myeloma

Authors:
- Tian‑Ze Ma
- Zhe Piao
- Sheng‑Yu Jin
- Yong‑Geun Kwak
View Affiliations

Affiliations: Department of Hematology, Yanbian University Hospital, Yanji, Jilin 133000, P.R. China, Department of Pharmacology, Chonbuk National University Medical School, Jeonju, Jeonbuk 560‑182, Republic of Korea
Published online on: November 23, 2018 https://doi.org/10.3892/etm.2018.7010
Pages: 649-656
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The exact cause instigating multiple myeloma (MM) has not been fully elucidated, and the disease has a median survival of 6 months without any treatment. To identify potential biomarkers of MM, serum proteins reflecting alteration in their proteomes were analyzed in 6 patients with MM compared with 6 healthy controls using two‑dimensional electrophoresis (2‑DE) and matrix‑assisted laser desorption/ionization time‑of flight mass spectrometry. The most notable differentially expressed proteins were validated by immunoblotting and changes in mRNA expression were evaluated by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). A total of 11 differentially expressed protein spots were found. The expression levels of 7 proteins [Immunoglobulin heavy constant µ; proto‑oncogene diffuse B-cell lymphoma (DBL2); 26S protease regulatory subunit 4 (P26s4); serum albumin; haptoglobin; and two unknown proteins with isoelectronic point (pI) of 6.41 and molecular weight of 35.4 kDa, and pI of 8.05 and molecular weight of 27.4 kDa, respectively] were downregulated in MM compared with healthy controls. Expression of gel actin‑related protein 2/3 complex subunit 1A (ARPC1A); immunoglobulin heavy constant γ 1; fibrinogen α chain (FGA) fragment D; and zinc finger protein 70 were increased in serum of MM patients. Protein expressions of ARPC1A, FGA, P26s4 and DBL2 were measured by immunoblotting in an independent cohort of 12 MM patients and 10 healthy controls. RT‑qPCR analysis demonstrated that ARPC1A expression only mimicked protein expression, whereas FGA, PSMC1 (encoding P26s4) and MCF2 (encoding DBL2) did not exhibit significant changes in mRNA expression between control and MM samples. These proteins represent putative serological biomarkers for patients with MM.

View Figures

View References

1	Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC and Rosen ST: Characterization of the MM.1 human multiple myeloma (MM) cell lines: A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 31:271–282. 2003. View Article : Google Scholar : PubMed/NCBI
2	Becker N: Epidemiology of multiple myeloma. Multiple myeloma. Springer; Berlin, Heidelberg: pp. 1832011
3	Rajkumar SV and Kumar S: Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc. 91:101–119. 2016. View Article : Google Scholar : PubMed/NCBI
4	Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 16:3832–3842. 1998. View Article : Google Scholar : PubMed/NCBI
5	Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, et al: Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 78:21–33. 2003. View Article : Google Scholar : PubMed/NCBI
6	Giuliani N, Colla S and Rizzoli V: New insight in the mechanism of osteoclast activation and formation in multiple myeloma: Focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol. 32:685–691. 2004. View Article : Google Scholar : PubMed/NCBI
7	Magrangeas F, Cormier ML, Descamps G, Gouy N, Lodé L, Mellerin MP, Harousseau JL, Bataille R, Minvielle S and Avet-Loiseau H: Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood. 103:3869–3875. 2004. View Article : Google Scholar : PubMed/NCBI
8	Bakkus MH, Heirman C, Van Riet I, Van Camp B and Thielemans K: Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood. 80:2326–2335. 1992.PubMed/NCBI
9	Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, Kashima K and Taniwaki M: The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood. 90:526–534. 1997.PubMed/NCBI
10	Gygi SP, Rochon Y, Franza BR and Aebersold R: Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 19:1720–1730. 1999. View Article : Google Scholar : PubMed/NCBI
11	Lian Z, Wang L, Yamaga S, Bonds W, Beazer-Barclay Y, Kluger Y, Gerstein M, Newburger PE, Berliner N and Weissman SM: Genomic and proteomic analysis of the myeloid differentiation program. Blood. 98:513–524. 2001. View Article : Google Scholar : PubMed/NCBI
12	Ota J, Yamashita Y, Okawa K, Kisanuki H, Fujiwara S, Ishikawa M, Lim Choi Y, Ueno S, Ohki R, Koinuma K, et al: Proteomic analysis of hematopoietic stem cell-like fractions in leukemic disorders. Oncogene. 22:5720–5728. 2003. View Article : Google Scholar : PubMed/NCBI
13	Zhang HT, Tian EB, Chen YL, Deng HT and Wang QT: Proteomic analysis for finding serum pathogenic factors and potential biomarkers in multiple myeloma. Chin Med J (Engl). 128:1108–1113. 2015. View Article : Google Scholar : PubMed/NCBI
14	Dowling P, Hayes C, Ting KR, Hameed A, Meiller J, Mitsiades C, Anderson KC, Clynes M, Clarke C, Richardson P and O'Gorman P: Identification of proteins found to be significantly altered when comparing the serum proteome from multiple Myeloma patients with varying degrees of bone disease. BMC Genomics. 15:9042014. View Article : Google Scholar : PubMed/NCBI
15	Hanash SM, Bobek MP, Rickman DS, Williams T, Rouillard JM, Kuick R and Puravs E: Integrating cancer genomics and proteomics in the post-genome era. Proteomics. 2:69–75. 2002. View Article : Google Scholar : PubMed/NCBI
16	Chance MR, Chang J, Schlatzer D and Miyagi M: Quantitative proteomics. Encyclopedia of analytical chemistry: Applications, theory and instrumentation. Meyers RA: John Wiley & Sons, Ltd; pp. 1–23. 2009
17	Scheler C, Lamer S, Pan Z, Li XP, Salnikow J and Jungblut P: Peptide mass fingerprint sequence coverage from differently stained proteins on two-dimensional electrophoresis patterns by matrix assisted laser desorption/ionization-mass spectrometry (MALDI-MS). Electrophoresis. 19:918–927. 1998. View Article : Google Scholar : PubMed/NCBI
18	Hellman U, Wernstedt C, Góñez J and Heldin CH: Improvement of an ‘In-Gel’ digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing. Anal Biochem. 224:451–455. 1995. View Article : Google Scholar : PubMed/NCBI
19	Shevchenko A, Wilm M, Vorm O and Mann M: Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 68:850–858. 1996. View Article : Google Scholar : PubMed/NCBI
20	Kwak JY, Ma TZ, Yoo MJ, Choi BH, Kim HG, Kim SR, Yim CY and Kwak YG: The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol. 32:836–842. 2004. View Article : Google Scholar : PubMed/NCBI
21	Clauser KR, Baker P and Burlingame AL: Role of accurate mass measurement (+/-10 ppm) in protein identification strategies employing MS or MS/MS and database searching. Anal Chem. 71:2871–2882. 1999. View Article : Google Scholar : PubMed/NCBI
22	Wang SB, Chen F, Sommerfeld M and Hu Q: Proteomic analysis of molecular response to oxidative stress by the green alga Haematococcus pluvialis (Chlorophyceae). Planta. 220:17–29. 2004. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Zhengfei D, Longping L, Xinghua W, et al: Measurement of serum levels of β2-microglobulin and high-sensitivity C-reactive protein in multiple myeloma and their clinical significances. China Healthcare Innovat. 6:0692008.
25	Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A, Galanis Z, Kalpadakis C, Dimou M, Kyriakou E, et al: Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol. 137:240–243. 2007. View Article : Google Scholar : PubMed/NCBI
26	Barnidge DR, Tschumper RC, Theis JD, Snyder MR, Jelinek DF, Katzmann JA, Dispenzieri A and Murray DL: Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS. J Proteome Res. 13:1905–1910. 2014. View Article : Google Scholar : PubMed/NCBI
27	Pan F, Egile C, Lipkin T and Li R: ARPC1/Arc40 mediates the interaction of the actin-related protein 2 and 3 complex with Wiskott-Aldrich syndrome protein family activators. J Biol Chem. 279:54629–54636. 2004. View Article : Google Scholar : PubMed/NCBI
28	Kahr WH, Pluthero FG, Elkadri A, Warner N, Drobac M, Chen CH, Lo RW, Li L, Li R, Li Q, et al: Loss of the Arp2/3 complex component ARPC1B causes platelet abnormalities and predisposes to inflammatory disease. Nat Commun. 8:148162017. View Article : Google Scholar : PubMed/NCBI
29	Malinova D, Fritzsche M, Nowosad CR, Armer H, Munro PM, Blundell MP, Charras G, Tolar P, Bouma G and Thrasher AJ: WASp-dependent actin cytoskeleton stability at the dendritic cell immunological synapse is required for extensive, functional T cell contacts. J Leukoc Biol. 99:699–710. 2016. View Article : Google Scholar : PubMed/NCBI
30	Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Laï JL, Daviet A, Li JY, Praloran V, Rapp MJ, Harousseau JL, et al: High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer. 24:9–15. 1999. View Article : Google Scholar : PubMed/NCBI
31	Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR and Pilarski LM: A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood. 92:2844–2855. 1998.PubMed/NCBI
32	Jo JC, Yoon DH, Kim S, Lee K, Kang EH, Jang S, Park CJ, Chi HS, Huh J, Park CS and Suh C: Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma. Ann Hematol. 93:463–469. 2014. View Article : Google Scholar : PubMed/NCBI
33	Frick PG: Inhibition of conversion of fibrinogen to fibrin by abnormal proteins in multiple myeloma. Am J Clin Pathol. 25:1263–1273. 1955. View Article : Google Scholar : PubMed/NCBI
34	Lopaciuk S, Snigurowicz J, Rostkowska J, Pniejnia-Olszynski W and Powiertowska-Rezmer M: Disorders in the conversion of fibrinogen to fibrin in patients with multiple myeloma. Acta Haematol Pol. 9:157–164. 1978.(In Polish). PubMed/NCBI
35	Lominadze D, Tsakadze N, Sen U, Falcone JC and D'Souza SE: Fibrinogen and fragment D-induced vascular constriction. Am J Physiol Heart Circ Physiol. 288:H1257–H1264. 2015. View Article : Google Scholar
36	Miller J, McLachlan AD and Klug A: Repetitive zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes. EMBO J. 4:1609–1614. 1985. View Article : Google Scholar : PubMed/NCBI
37	Jeong HS, Jeong IC, Kim A, Kang SW, Kang HS, Kim YJ, Lee SH and Park JS: Cloning of the large subunit of replication protein A (RPA) from yeast Saccharomyces cerevisiae and its DNA binding activity through redox potential. J Biochem Mol Biol. 35:194–198. 2002.PubMed/NCBI
38	Unoki M, Okutsu J and Nakamura Y: Identification of a novel human gene, ZFP91, involved in acute myelogenous leukemia. Int J Oncol. 22:1217–1223. 2003.PubMed/NCBI
39	Li W, Zhang H, Min P, Zhu J, Xu D, Jiang W, Ma Y, Qiu J, Xu W, Chen J, et al: Downregulated miRNA-1269a variant (rs73239138) decreases the susceptibility to gastric cancer via targeting ZNF70. Oncol Lett. 14:6345–6354. 2017.PubMed/NCBI
40	Westwick JK, Lee RJ, Lambert QT, Symons M, Pestell RG, Der CJ and Whitehead IP: Transforming potential of Dbl family proteins correlates with transcription from the cyclin D1 promoter but not with activation of Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun. J Biol Chem. 273:16739–16747. 1998. View Article : Google Scholar : PubMed/NCBI
41	Zhu K, Debreceni B, Bi F and Zheng Y: Oligomerization of DH domain is essential for Dbl-induced transformation. Mol Cell Biol. 21:425–437. 2001. View Article : Google Scholar : PubMed/NCBI
42	Thompson HG, Harris JW and Brody JP: Post-translationally modified S12, absent in transformed breast epithelial cells, is not associated with the 26S proteasome and is induced by proteasome inhibitor. Int J Cancer. 111:338–347. 2004. View Article : Google Scholar : PubMed/NCBI
43	Kim JE, Yoo C, Lee DH, Kim SW, Lee JS and Suh C: Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol. 89:391–397. 2010. View Article : Google Scholar : PubMed/NCBI
44	Dimopoulos M, Gika D, Zervas K, Kyrtsonis M, Symeonidis A, Anagnostopoulos A, Bourantas K, Matsouka C and Pangalis G: The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia. Leuk Lymphoma. 45:1809–1813. 2004. View Article : Google Scholar : PubMed/NCBI
45	Chen JH, Hsu SN, Huang TC, Wu YY, Lin C, Chang PY, Chen YC and Ho CL: Prognostic significance of initial serum albumin and 24 h daily protein excretion before treatment in multiple myeloma. PLoS One. 10:e01289052015. View Article : Google Scholar : PubMed/NCBI
46	Allison AC: Structure and function of plasma. Plenum Press; New York, NY: pp. 55–72. 1974
47	Langlois MR and Delanghe JR: Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 42:1589–1600. 1996.PubMed/NCBI
48	Sutton HE: The haptoglobins. Prog Med Genet. 7:163–216. 1970.PubMed/NCBI
49	San Miguel J, Vicente V, Battle J, Hernandez F and Lopez Borrasca A: Acute phase reactants and clinical stages in multiple myeloma. Neoplasma. 28:333–338. 1981.PubMed/NCBI